Pharming Group Overview

  • Founded

  • 1988

Founded
  • Status

  • Public

  • Employees

  • 332

Employees
  • Stock Symbol

  • PHARM

Stock Symbol
  • Investments

  • 8

  • Share Price

  • $1.23

  • (As of Tuesday Closing)

Pharming Group General Information

Description

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.

Contact Information

Website
www.pharming.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Other Commercial Services
Stock Exchange
AMS
Primary Office
  • Darwinweg 24
  • 2333 CR Leiden
  • Netherlands
+31 071 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharming Group Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.23 $1.27 $0.69 - $1.54 $809M 656M 11.5M

Pharming Group Financials Summary

In Thousands,
USD 		TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 830,841 704,305 548,434 969,182
Revenue 201,546 205,622 198,871 212,174
EBITDA 17,178 30,232 39,354 57,637
Net Income (1,995) 13,674 15,996 37,746
Total Assets 422,996 425,797 397,315 418,453
Total Debt 170,399 166,694 161,761 161,959
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharming Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses o
Pharmaceuticals
Leiden, Netherlands
332 As of 2022
00000
000000000 00000

00000

e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labor
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
0.00 0000-00-00
00000000000 000.00

000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
Hamburg, Germany
0000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pharming Group Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
000000 Formerly PE-Backed Hamburg, Germany 0000 00000 000000000 00000
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
000000 Formerly PE-Backed Bengaluru, India 00000 000.00 00000000 000.00
000000 00000000000 Formerly PE-Backed South San Francisco, CA 00 00000 000000&0 00000
You’re viewing 5 of 29 competitors. Get the full list »

Pharming Group Patents

  • 202

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Pharming Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3175603-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Pending 17-Apr-2020 000000000
EP-3895726-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Inactive 17-Apr-2020 000000000 00
EP-4135756-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Pending 17-Apr-2020 000000000
US-20210324107-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Pending 17-Apr-2020 000000000
AU-2019226355-A1 Treatment and prevention of pre-eclampsia Pending 28-Feb-2018 A61K38/57
To view Pharming Group’s complete patent history, request access »

Pharming Group Executive Team (16)

Name Title Board Seat Contact Info
Sijmen de Vries MD Chief Executive Officer, Executive Director & Board Member
Jeroen Wakkerman Chief Financial Officer, Finance
Mireille Sanders Chief Operating Officer, Operations
Stephen Toor General Manager & Executive
Ruud van Outersterp Chief Ethics & Compliance Officer
You’re viewing 5 of 16 executive team members. Get the full list »

Pharming Group Board Members (13)

Name Representing Role Since
A. De Winter Pharming Group Chairman of the Audit Committee and member of the Corporate Governance Committee 000 0000
Barbara Yanni JD Self Board Member 000 0000
Deborah Jorn Pharming Group Vice-Chairwoman of the Board of Directors, Member of the Audit Committee and Chairwoman of the Remuneration Committee 000 0000
Leonard Kruimer Self Board Member 000 0000
Mark Pykett Ph.D Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Pharming Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharming Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 01-Jan-2020 000000000 Buildings and Property
00000000 (000 13-Aug-2019 000000000 0000 Buildings and Property
0000000000000 09-Apr-2019 000000000 00.000 BPO/Outsource Services 000000 00
0000000000000 09-Apr-2019 000000000 BPO/Outsource Services 000000 00
Ruconest (North American commercialization rights) 08-Dec-2016 Corporate Asset Purchase 00000 Buildings and Property
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Pharming Group ESG

Risk Overview

Risk Rating

Updated November, 08, 2022

27.93 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,233

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 866

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 382

Rank

00.00

Percentile

To view Pharming Group’s complete esg history, request access »

Pharming Group Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 23-Mar-2006 000000000000000000 Completed
  • 00000000 00000
To view Pharming Group’s complete exits history, request access »